RNA | Jotup

Global gRNA Market to Surpass USD 1.62 Billion by 2030 with Robust Growth in Next-Generation Sequencing and Genome Engineering Applications - ResearchAndMarkets.com

Retrieved on:

Thursday, March 14, 2024

The global gRNA (guide RNA) market is witnessing an unprecedented surge, with projections estimating its growth to reach USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030.

Key Points:

The global gRNA (guide RNA) market is witnessing an unprecedented surge, with projections estimating its growth to reach USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030.
The latest market report on the global gRNA industry, now available for review, emphasizes the utility of products and custom gRNA synthesis services, and the ever-expanding realm of research applications.
Pharmaceutical and biotechnology companies are leveraging gRNA to pioneer advancements in precision medicine, positioning themselves as key end-users and market growth propellants.
The integration of advanced technologies and the discovery of novel applications are key to sustaining this growth momentum.

Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech

Retrieved on:

Thursday, March 14, 2024

Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, RNA, Genomics, CHF, HQ, Vaccine

Alithea Genomics , an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing.

Key Points:

Alithea Genomics , an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing.
The round was led by the Novalis Biotech Acceleration fund and included new investor TechU Ventures alongside existing investors.
“Since our initial seed investment, the Alithea team has delivered on all its milestones and exceeded our expectations in the progress being made,” said Jan Van den Berghe, co-founder and managing director of Novalis Biotech.
“With the additional proceeds from this seed extension, we will be able to continue to expand and grow,” said Riccardo Dainese, CEO and co-founder of Alithea Genomics.

Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement

Retrieved on:

Wednesday, March 13, 2024

Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.

Key Points:

Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
In 2022, Ricoh completed the acquisition of Elixirgen Scientific, Inc. (Baltimore, Maryland, USA).
Ricoh continues to contribute to the acceleration of drug development research through the diverse solutions provided by Elixirgen Scientific.
Summit Pharmaceuticals International Corporation (Chiyoda-ku, Tokyo, Japan), a subsidiary of Sumitomo Corporation (Chiyoda-ku, Tokyo, Japan), is the exclusive representative of ERS Genomics in Japan.

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on:

Wednesday, March 13, 2024

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points:

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
“These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Retrieved on:

Wednesday, March 13, 2024

Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MD, Patient, Cardiovascular disease, Small RNA, RNA, Moyamoya disease, ASCVD, Mole, Therapy, Tutoring

Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.

Key Points:

Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.
These data demonstrated a highly significant reduction from baseline in Lp(a) compared to placebo to 36 weeks (primary endpoint).
Median percentage reduction in Lp(a) of 90% or greater were observed for both doses at week 36.
“We are excited about the emerging phase 2 data, which are very consistent with phase 1 results and support a competitive profile for treating patients with high Lp(a),” said Steven Romano, MD, Head of Research and Development at Silence.

Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists

Retrieved on:

Tuesday, March 12, 2024

Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

Key Points:

Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.
As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext® and CancerNext-Expanded® assays.
“Tempus has a powerful offering for tissue and liquid biopsy DNA and RNA profiling and somatic testing.
Now, with our germline testing and variant assessment expertise behind Tempus xG and xG+, we are poised to create a future where paired somatic and germline testing is the standard.

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024

Retrieved on:

Tuesday, March 12, 2024

Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Online, Toxicity, Nutcracker, Prostate cancer, RNA, Cervical intraepithelial neoplasia, Abstract, AACR, Therapy, Antigen

The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.

Key Points:

The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.
The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470.
This therapy is designed to target prostate cancer antigens with mRNA-encoded, multi-specific T cell engagers with a strong anti-tumor effect and low toxicity.
The 2024 AACR Annual Meeting takes place in San Diego from April 5-10.

Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting

Retrieved on:

Monday, March 11, 2024

Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, AACR, RNA, Cell

Ribometrix , a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Key Points:

Ribometrix , a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
The posters will show in vivo anti-tumor efficacy of Ribometrix’s lead candidate targeting the RNA-binding protein eIF4E in combination with standard-of-care across multiple indications, and the Company’s discovery of small molecules that directly bind a complex RNA structure within the c-MYC mRNA in cells, and demonstrate a reduction in c-MYC protein levels.
These new data support the potential for Ribometrix’s RNA-modulating approach to enable drugging well-validated therapeutic targets, including eIF4E and c-MYC, that are currently intractable to traditional small molecule approaches.

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System

Retrieved on:

Thursday, April 4, 2024

IRP, Central nervous system, Patient, Research, RNA, Mina, RNAa, Therapy, Bone marrow, Pharmaceutical industry

The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.

Key Points:

The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.
"We are incredibly proud of our IRP division and the work it is doing with the great team at MiNA Therapeutics," said NS Pharma President Tsugio Tanaka.
Through this agreement, MiNA Therapeutics will provide Nippon Shinyaku RNAa therapeutics, which are oligonucleotides that can increase the transcription of a target gene.
"Through this research alliance with MiNA Therapeutics, we will continue our efforts to apply our nucleic acid drug technology in the central nervous system," Tanaka stated.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays

Retrieved on:

Thursday, April 4, 2024

PCR, QC, Gene, Data analysis, RT, Bias, BCR, Calibration, NGS, Biomarker, Research, RNA, Messenger, Workflow, Immunity, TCR, Collection, AIR, Vaccine

MOUNTAIN VIEW, Calif., April 4, 2024 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.

Key Points:

The first-to-market DriverMap™ AIR RNA TCR/BCR spike-in calibration controls measure the accuracy, sensitivity, and linear range of sequencing-based immune repertoire profiling assays.
The DriverMap™ AIR RNA Spike-In Controls' key characteristics include:
These controls consist of 48 B-Cell Receptor (BCR) and 39 T-Cell Receptor (TCR) synthetic mRNA constructs designed to mimic all the different and most abundant TCR and BCR genes.
These standards and controls will help attain the goal of more reliable and reproducible AIR sequencing (AIR-Seq) data harmonization, interpretation, and sharing.
For more information on the DriveMap AIR RNA Spike-In Controls, including introductory pricing, visit www.cellecta.com/DriverMapAIR or email [email protected] .